Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab ADC 1
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab ADC 1 refers to an antibody-drug conjugate (ADC) that utilizes the HER2-targeted monoclonal antibody trastuzumab (or a biosimilar/derivative thereof) conjugated to a cytotoxic payload (such as a microtubule inhibitor like DM1 or MMAE, or a topoisomerase I inhibitor like DXd) via a chemical linker. Trastuzumab ADCs are designed to selectively deliver highly potent cytotoxic agents to HER2-expressing cancer cells, minimizing systemic toxicity. Upon binding to HER2 on the cell surface, the ADC is internalized via receptor-mediated endocytosis, and the payload is released intracellularly to induce cell death. Examples of approved trastuzumab ADCs include ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (T-DXd).
- Other names
- trastuzumab ADCtrastuzumab antibody-drug conjugate
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab ADC 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab ADC 1.